← Back to Search

Cannabinoid

Cannabis for Cognitive Impairment

Phase 1
Waitlist Available
Led By Dustin C Lee, PhD
Research Sponsored by Johns Hopkins University
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up pre-administration, post-administration, 2, 4 hours

Summary

This trial aims to see how well eye movements can detect impairment from THC, whether previous cannabis use affects this, and how it relates to attention span. They will give different doses of THC to frequent and

Who is the study for?
This trial is for frequent and infrequent cannabis users to study how THC affects eye movements and attention. Participants must be able to consume THC and perform tasks that test their oculomotor function and sustained attention.
What is being tested?
The study tests the effects of different doses of THC (0, 5mg, 30mg) on eye movement control and concentration in both regular and occasional cannabis users using a double-blind, placebo-controlled crossover design.
What are the potential side effects?
Possible side effects from THC may include altered sensory perceptions, mood changes, difficulty with thinking or problem-solving, impaired memory, coordination issues, anxiety or paranoia.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~pre-administration, post-administration, 2, 4 hours
This trial's timeline: 3 weeks for screening, Varies for treatment, and pre-administration, post-administration, 2, 4 hours for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Commission Errors
Omission Errors
Reaction Time
+2 more
Secondary study objectives
Antisaccade
Memory-Guided
Saccade Speed
+1 more

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 5 mg THCExperimental Treatment1 Intervention
Inhaled cannabis - 5 mg THC
Group II: 30 mg THCExperimental Treatment1 Intervention
Inhaled cannabis - 30 mg THC
Group III: 0 mg THCPlacebo Group1 Intervention
Inhaled Cannabis - 0 mg THC
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Cannabis
2014
Completed Phase 3
~780

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

National Institute on Drug Abuse (NIDA)NIH
2,579 Previous Clinical Trials
3,316,885 Total Patients Enrolled
Johns Hopkins UniversityLead Sponsor
2,321 Previous Clinical Trials
14,873,898 Total Patients Enrolled
Dustin C Lee, PhDPrincipal InvestigatorJohns Hopkins University
1 Previous Clinical Trials
50 Total Patients Enrolled
~27 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top